239 related articles for article (PubMed ID: 26359224)
1. Advancing pharmacological treatment options for advanced gastric cancer.
Sudo K; Yamada Y
Expert Opin Pharmacother; 2015; 16(15):2293-305. PubMed ID: 26359224
[TBL] [Abstract][Full Text] [Related]
2. Second-line chemotherapy for patients with advanced gastric cancer.
Takahari D
Gastric Cancer; 2017 May; 20(3):395-406. PubMed ID: 28260227
[TBL] [Abstract][Full Text] [Related]
3. Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
Bilici A
World J Gastroenterol; 2014 Apr; 20(14):3905-15. PubMed ID: 24744580
[TBL] [Abstract][Full Text] [Related]
4. Influence of Taxanes on Treatment Sequence in Gastric Cancer.
Lorenzen S; Stahl M; Hofheinz RD; Al-Batran SE; Lordick F
Oncol Res Treat; 2020; 43(1-2):42-47. PubMed ID: 31634892
[TBL] [Abstract][Full Text] [Related]
5. Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer.
Garrido M; Fonseca PJ; Vieitez JM; Frunza M; Lacave AJ
Expert Rev Anticancer Ther; 2014 Aug; 14(8):887-900. PubMed ID: 24953238
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
De Vita F; Giuliani F; Silvestris N; Catalano G; Ciardiello F; Orditura M
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S11-5. PubMed ID: 21129604
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
Weissinger F; Reymond M; Dumke K; Krüger M
Onkologie; 2011; 34(10):548-51. PubMed ID: 21985855
[TBL] [Abstract][Full Text] [Related]
8. Advanced gastric adenocarcinoma: optimizing therapy options.
Mizrak Kaya D; Harada K; Shimodaira Y; Amlashi FG; Lin Q; Ajani JA
Expert Rev Clin Pharmacol; 2017 Mar; 10(3):263-271. PubMed ID: 28094573
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane- and trastuzumab-naïve patients with HER2-positive, previously treated, advanced, or recurrent gastric cancer (JFMC45-1102).
Nishikawa K; Takahashi T; Takaishi H; Miki A; Noshiro H; Yoshikawa T; Nishida Y; Iwasa S; Miwa H; Masuishi T; Boku N; Yamada Y; Kodera Y; Yoshida K; Morita S; Sakamoto J; Saji S; Kitagawa Y
Int J Cancer; 2017 Jan; 140(1):188-196. PubMed ID: 27521503
[TBL] [Abstract][Full Text] [Related]
11. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
Garrido M
Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
[TBL] [Abstract][Full Text] [Related]
12. Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV; Chao J; Muro K; Al-Batran SE; Klempner SJ; Wainberg ZA; Shah MA; Rha SY; Ohtsu A; Liepa AM; Knoderer H; Chatterjee A; Van Cutsem E
Oncologist; 2021 Oct; 26(10):e1704-e1729. PubMed ID: 34288262
[TBL] [Abstract][Full Text] [Related]
13. Molecular-targeted therapy for chemotherapy-refractory gastric cancer: a case report and literature review.
Kuo HY; Yeh KH
Anticancer Res; 2014 Jul; 34(7):3695-9. PubMed ID: 24982389
[TBL] [Abstract][Full Text] [Related]
14. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2.
Hayashi K; Nagasaki E; Nakada K; Tamura M; Arakawa Y; Uwagawa T; Yano S
J Infect Chemother; 2018 Apr; 24(4):298-301. PubMed ID: 29174919
[TBL] [Abstract][Full Text] [Related]
16. Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
Kim R; Tan A; Choi M; El-Rayes BF
Crit Rev Oncol Hematol; 2013 Nov; 88(2):416-26. PubMed ID: 23764501
[TBL] [Abstract][Full Text] [Related]
17. [Second-line treatment for metastatic or locally advanced gastric cancer].
Li KC; Cheng SY; Du J; Li J
Zhonghua Zhong Liu Za Zhi; 2016 Oct; 38(10):721-724. PubMed ID: 27784452
[TBL] [Abstract][Full Text] [Related]
18. Medical management of gastric cancer: a 2014 update.
Elimova E; Shiozaki H; Wadhwa R; Sudo K; Chen Q; Estrella JS; Blum MA; Badgwell B; Das P; Song S; Ajani JA
World J Gastroenterol; 2014 Oct; 20(38):13637-47. PubMed ID: 25320502
[TBL] [Abstract][Full Text] [Related]
19. Hopes and failures in front-line advanced HER2-positive gastric cancer therapy.
Kong F; Yao Y; Deng R; Li X; Jia Y
Anticancer Drugs; 2021 Aug; 32(7):675-680. PubMed ID: 33929993
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
